Approaches to handling data when a phase II trial deviates from the pre-specified Simon's two-stage design.
Simon's 'optimal' and 'minimax' two-stage designs are common methods for conducting phase IIA studies investigating new cancer therapies. However, these designs are rather rigid in their settings because of the pre-specified rejection rules and fixed sample sizes at each stage. In practice, we often encounter the problem that a study is unable to adhere to the event number and sample sizes of the original two-stage design. In this paper, we consider some approaches in handling situations where deviations or interruptions from the original Simon's two-stage design occur because recruitment of patients is slower than expected. We consider four scenarios and use conditional probabilities to address the issues commonly inquired by the scientific review board. We also discuss how to report p-values in these situations.
Wu
Yujun
Y
Department of Biostatistics and Programming, Sanofi-Aventis, Bridgewater, NJ, USA.
Shih
Weichung J
WJ
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D001699:Biometry / Q000379:methods*; D017322:Clinical Trials, Phase II as Topic / Q000706:statistics & numerical data*; D003627:Data Interpretation, Statistical; D005260:Female; D006801:Humans; D015233:Models, Statistical; D011336:Probability; D013269:Stochastic Processes; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy
Biometrics. 1982 Mar;38(1):143-51
7082756
Biometrics. 2004 Jun;60(2):482-90
15180674
Control Clin Trials. 2001 Apr;22(2):117-25
11306150
Biometrics. 1984 Sep;40(3):797-803
6518248
Control Clin Trials. 1989 Mar;10(1):1-10
2702835
Stat Med. 2004 Feb 28;23(4):561-9
14755389
Control Clin Trials. 1996 Dec;17(6):526-35
8974211
Stat Med. 2006 Mar 30;25(6):933-41
16220505
J Biopharm Stat. 2006;16(6):765-75; discussion 777-83
17146978
Stat Med. 2007 Mar 30;26(7):1462-72
16900560
Stat Med. 1992 May;11(7):853-62
1604065